SoFi CEO enters prepaid forward contract on 1.5 million shares
Cathie Wood’s ARK ETFs have disclosed their daily trades for Wednesday, August 27th, 2025, with significant activity in the tech and biotech sectors. Leading the charge was a substantial investment in Bitmine Immersion Technologies Inc (OTC:BMNR), where ARK acquired a total of 339,113 shares across three of its funds—ARKK, ARKW, and ARKF—with a total value of approximately $16.94 million.
ARK also continued to increase its stake in CRISPR Therapeutics AG (NASDAQ:CRSP), purchasing 124,275 shares through its ARKK ETF, amounting to a $6.82 million investment. This move follows a pattern of consistent buying in CRISPR over the past week, signaling a bullish stance on the gene-editing company’s future.
On the selling side, ARK divested from DraftKings Inc (NASDAQ:DKNG), offloading a total of 266,052 shares across the same three ETFs for a total value of nearly $12.69 million. This sale marks a continuation of ARK’s reducing position in the online sports betting company, which has been evident in recent trading sessions.
Additionally, ARK bolstered its position in Intellia Therapeutics Inc (NASDAQ:NTLA) by buying 185,200 shares through ARKK, with a total value of $2.10 million. This follows a series of purchases in Intellia, underscoring ARK’s confidence in the biotechnology firm specializing in genome editing.
In contrast, ARK sold 85,278 shares of Roku Inc (NASDAQ:ROKU) from its ARKK ETF, valued at approximately $8.15 million. The sale continues a trend of ARK reducing its exposure to the streaming device company, as observed in the last few trading days.
Investors and market watchers tracking ARK’s movements will note the ETF’s strategic shifts, with a clear focus on innovative and disruptive companies in the technology and biotech industries. As always, these daily trade reports provide insight into Cathie Wood’s investment strategy, offering a glimpse into where ARK sees potential growth and where it is choosing to cut back.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.